A chimeric approach is used to discover microtubule disruptors with excellent in vitro activity and oral bioavailability; a ligand–protein interaction with carbonic anhydrase that enhances bioavailability is characterised by protein X-ray crystallography. Dosing of a representative chimera in a tumour xenograft model confirms the excellent therapeutic potential of the class.